FDA Drug recall D-1104-2023
All Over-The-Counter (OTC) drug products warehoused, salvaged, and sold by Inmar
- FDA Drug
- Class II
- ongoing
- Published 2023-08-30
On 2023-08-30 the FDA classified a Class II recall of All Over-The-Counter (OTC) drug products warehoused, salvaged, and sold by Inmar by Inmar Supply Chain Solutions, citing CGMP Deviations: Potential exposure to rodents and rodent activity in the distribution center. Also, due to unusually hot weather, FDA Recalled Products may have been subjected to….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1104-2023 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2023-08-14 |
| Published | 2023-08-30 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Inmar Supply Chain Solutions |
| Distribution | n/a |
Product
All Over-The-Counter (OTC) drug products warehoused, salvaged, and sold by Inmar.
Reason
CGMP Deviations: Potential exposure to rodents and rodent activity in the distribution center. Also, due to unusually hot weather, FDA Recalled Products may have been subjected to temperatures in excess of storage condition instructions on product labeling.
Identifiers
| code_info | Miscellaneous |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1104-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.